Cerenome, Inc. (CNSY)
NASDAQ: CNSY · Real-Time Price · USD
0.6301
-0.0723 (-10.29%)
At close: Nov 20, 2026, 4:00 PM EST
0.6300
-0.0001 (-0.02%)
After-hours: Nov 20, 2026, 7:57 PM EST
Cerenome Revenue
Cerenome had revenue of $722.00K in the quarter ending September 30, 2026, a decrease of -48.32%. This brings the company's total for the last twelve months to $3.53M, down -32.90% year-over-year. In the year 2025, Cerenome had annual revenue of $5.21M, down -10.49%. That makes Cerenome the 41,080th largest company in the world by revenue and 5,522nd in the United States.
Revenue (ttm)
$3.53M
Revenue Growth
-32.90%
P/S Ratio
1.36
Revenue / Employee
$126,000
Employees
28
Market Cap
4.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.21M | -611.00K | -10.49% |
| Dec 31, 2024 | 5.82M | 911.00K | 18.54% |
| Dec 31, 2023 | 4.91M | 4.69M | 2,093.30% |
| Dec 31, 2022 | 224.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 303.00K | -6.70M | -95.67% |
| Dec 31, 2019 | 7.00M | 4.02M | 134.60% |
| Dec 31, 2018 | 2.98M | -739.00K | -19.85% |
| Dec 31, 2017 | 3.72M | -3.00M | -44.65% |
| Dec 31, 2016 | 6.72M | -97.00K | -1.42% |
| Dec 31, 2015 | 6.82M | 4.18M | 157.88% |
| Dec 31, 2014 | 2.65M | -2.43M | -47.87% |
| Dec 31, 2013 | 5.07M | -718.00K | -12.40% |
| Dec 31, 2012 | 5.79M | 3.78M | 187.73% |
| Dec 31, 2011 | 2.01M | -360.00K | -15.17% |
| Dec 31, 2010 | 2.37M | -6.52M | -73.32% |
| Dec 31, 2009 | 8.89M | 6.57M | 282.49% |
| Dec 31, 2008 | 2.33M | -2.93M | -55.77% |
| Dec 31, 2007 | 5.26M | -1.22M | -18.82% |
| Dec 31, 2006 | 6.48M | 6.11M | 1,645.55% |
| Dec 31, 2005 | 371.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| SeaStar Medical Holding | 2.17M |
| Evogene | 1.49M |
| Kiora Pharmaceuticals | 1.00M |
| Can-Fite BioPharma | 405.00K |
| Pulmatrix | 3.00K |
| Soligenix | 2.34K |
CNSY News
- 4 days ago - Cerenome price target raised to $7 from $1 at H.C. Wainwright - TheFly
- 6 days ago - Cerenome Earnings Call Transcript: Q3 2026 - Transcripts
- 6 days ago - Cerenome Earnings release: Q3 2026 - Filings
- 6 days ago - Cerenome Quarterly report: Q3 2026 - Filings
- 6 days ago - Cerenome announces interim data from ReSPECT-LM study of Reyobiq - TheFly
- 6 days ago - Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting - GlobeNewsWire
- 8 days ago - Cerenome reports Q3 EPS ($1.14), consensus ($1.03) - TheFly
- 8 days ago - Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress - GlobeNewsWire